Centro Dermatológico Dr Ladislao de la Pascua, Ciudad de México, Mexico,
Centro Dermatológico Dr Ladislao de la Pascua, Ciudad de México, Mexico.
Dermatology. 2021;237(6):952-960. doi: 10.1159/000511890. Epub 2021 Jan 22.
Vitiligo has an unpredictable course and a variable response to treatment. Furthermore, the improvement of some vitiligo lesions cannot be considered a guarantee of a similar response to the other lesions. Instruments for patient-reported outcome measures (PROM) can be an alternative to measure complex constructions such as clinical evolution.
The aim of this study was to validate a PROM that allows to measure the clinical evolution of patients with nonsegmental vitiligo in a simple but standardized way that serves to gather information for a better understanding of the disease.
The instrument was created through expert consensus and patient participation. For the validation study, a prospective cohort design was performed. The body surface area affected was measured with the Vitiligo Extension Score (VES), the extension, the stage, and the spread by the evaluation of the Vitiligo European Task Force assessment (VETFa). Reliability was determined with test-retest, construct validity through hypothesis testing, discriminative capacity with extreme groups, and response capacity by comparing initial and final measurements.
Eighteen semi-structured interviews and 7 cognitive interviews were conducted, and 4 dermatologists were consulted. The instrument Clinical Evolution-Vitiligo (CV-6) was answered by 119 patients with a minimum of primary schooling. A wide range was observed in the affected body surface; incident and prevalent cases were included. The average time to answer the CV-6 was 3.08 ± 0.58 min. In the test-retest (n = 53), an intraclass correlation coefficient was obtained: 0.896 (95% CI 0.82-0.94; p < 0.001). In extreme groups, the mean score was 2 (2-3) and 5 (4-6); p < 0.001. The initial CV-6 score was different from the final one and the change was verified with VES and VETFa (p < 0.05, n = 92).
The CV-6 instrument allows patient collaboration, it is simple and brief, and it makes it easier for the doctor to focus attention on injuries that present changes at the time of medical consultation.
白癜风的病程不可预测,治疗反应也各不相同。此外,某些白癜风病变的改善并不能保证对其他病变有类似的反应。患者报告结局测量(PROM)工具可以作为衡量复杂结构的替代方法,例如临床演变。
本研究旨在验证一种 PROM,该 PROM 能够以简单但标准化的方式衡量非节段性白癜风患者的临床演变,为更好地了解疾病提供信息。
该工具是通过专家共识和患者参与创建的。在验证研究中,采用前瞻性队列设计。使用白癜风扩展评分(VES)测量受影响的体表面积,使用白癜风欧洲工作组评估(VETFa)评估扩展、阶段和扩散。通过测试-重测、通过假设检验确定信度、通过极端组确定判别能力、通过比较初始和最终测量值确定反应能力。
进行了 18 次半结构式访谈和 7 次认知访谈,并咨询了 4 位皮肤科医生。该仪器 Clinical Evolution-Vitiligo(CV-6)由至少接受过小学教育的 119 名患者回答。观察到受影响的体表面积范围很广;包括偶发性和普遍性病例。回答 CV-6 的平均时间为 3.08 ± 0.58 分钟。在测试-重测(n = 53)中,获得了组内相关系数:0.896(95%CI 0.82-0.94;p < 0.001)。在极端组中,平均分数为 2(2-3)和 5(4-6);p < 0.001。初始 CV-6 评分与最终评分不同,并且通过 VES 和 VETFa 验证了变化(p < 0.05,n = 92)。
CV-6 工具允许患者合作,它简单而简洁,使医生更容易在就诊时关注出现变化的损伤。